Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.75 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.75 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.75 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.67 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 0.67 |
| ▸ | BRD4 | O60885 | 15/20 | 0.66 |
| ▸ | BRDT | Q58F21 | 13/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.63 |
| ▸ | CLK2 | P49760 | 3/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.63 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.63 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.63 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.63 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.63 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.63 |
| ▸ | PRKCG | P05129 | 2/20 | 0.63 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.63 |
| ▸ | NEK4 | P51957 | 2/20 | 0.63 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098789 | 1.00 | PLK1 (0.75) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL10098781 | 0.93 | PLK1 (0.69) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL618641 | 0.93 | PLK1 (0.69) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL619364 | 0.91 | PLK1 (0.69) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL13611485 | 0.91 | PLK1 (0.69) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL4299436 | 0.91 | PLK1 (0.69) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL2397131 | 0.91 | PLK1 (0.69) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL618948 | 0.89 | PLK1 (0.74) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL10098805 | 0.89 | PLK1 (0.74) | PLK1MAPK7DYRK1APLK3PLK2 | |
| SCHEMBL10098783 | 0.88 | BRD4 (0.73) | PLK1MAPK7DYRK1APLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | claimed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| EP-2379559-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | claimed |
| EP-3255047-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND USES IN TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | PLK1 109/4885MAPK7 263/4885DYRK1A 363/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | PLK1 31/4885MAPK7 295/4885DYRK1A 670/4885 |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | PLK1 110/4885MAPK7 253/4885DYRK1A 350/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | PLK1 31/4885MAPK7 295/4885DYRK1A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.